Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

BACKGROUND: Indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease (COPD). OBJECTIVES: This study compared the onset of action of single doses of indacaterol 150 and 300 μg with salbutamol 200 μg, salmeterol-fluticasone 50...

Descripción completa

Detalles Bibliográficos
Autores principales: Balint, Beatrix, Watz, Henrik, Amos, Carolynn, Owen, Roger, Higgins, Mark, Kramer, Benjamin
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939686/
https://www.ncbi.nlm.nih.gov/pubmed/20856830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939686/
https://www.ncbi.nlm.nih.gov/pubmed/20856830

Ejemplares similares